Novo Nordisk contends CMS violated IRA by lumping products

CMS’s decision to treat several of Novo Nordisk’s insulin products as a single product that is subject to price negotiation under the Inflation Reduction Act was a surprise. The company says it is also illegal, and it is asking a federal court to prevent CMS from including its insulin products in the Medicare drug price negotiation program.

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) filed a lawsuit on Sept. 29, hours after a federal judge denied the U.S. Chamber of Commerce’s request for a preliminary injunction that would have prevented CMS from implementing the IRA’s Medicare drug price negotiation program. ...